LOADING

Type to search

HiberCell Launches With $60.75 Million Series A to Target Dormant Metastatic Cancer Cells

BioTech

HiberCell Launches With $60.75 Million Series A to Target Dormant Metastatic Cancer Cells

Share
hibercell-launches-with-60.75-million-series-a-to-target-dormant-metastatic-cancer-cells

Recurrence of cancer, which is the cause of many cancer deaths, is driven by dormant disseminated tumor cells (DTCs) that remain undetected in the body for long periods of time. HiberCell is working to develop first-in-class drugs that target DTCs that originate from solid and liquid tumors.

Leave a Comment

Your email address will not be published. Required fields are marked *